SEATTLE, March 23 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has filed its annual report on Form 10-K for the year ended December 31, 2008. This filing is available for review on CTI's website at http://www.CellTherapeutics.com, or on the Securities and Exchange Commission's web site at www.sec.gov.
As required under NASDAQ Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.